Literature DB >> 32037278

Human microbiome is a diagnostic biomarker in hepatocellular carcinoma.

Ben-Chen Rao1, Jia-Min Lou1, Wei-Jie Wang2, Ang Li1, Guang-Ying Cui1, Zu-Jiang Yu1, Zhi-Gang Ren3.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. Increasing evidence indicates a close relationship between HCC and the human microbiota. Herein, we reviewed the important potential of the human microbiota as a diagnostic biomarker of HCC. DATA SOURCES: Several innovative studies have investigated the characteristics of the gut and oral microbiomes in patients with HCC and proposed that the human microbiome has the potential to be a diagnostic biomarker of HCC. Literature from February 1999 to February 2019 was searched in the PubMed database using the keywords "microbiota" or "microbiome" or "microbe" and "liver cancer" or "hepatocellular carcinoma", and the results of clinical and experimental studies were analyzed.
RESULTS: Specific changes occur in the human microbiome of patients with HCC. Moreover, the gut microbiome and oral microbiome can be used as non-invasive diagnostic biomarkers for HCC. Furthermore, they also have certain diagnostic potential for precancerous diseases of HCC. The diagnostic potential of the blood microbiota and ascites microbiota in HCC will be gradually discovered in the future.
CONCLUSIONS: The human microbiome is valuable to the diagnosis of HCC and provides a novel strategy for targeted therapy of HCC. The human microbiome may be widely used in the diagnosis, treatment and prognosis for multiple system diseases or cancers in the future.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Diagnostic biomarker; Gut microbiome; Hepatocellular carcinoma; Human microbiome; Oral microbiome

Mesh:

Substances:

Year:  2020        PMID: 32037278     DOI: 10.1016/j.hbpd.2020.01.003

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  4 in total

Review 1.  The Gut Microbiome and Hepatocellular Carcinoma: Implications for Early Diagnostic Biomarkers and Novel Therapies.

Authors:  Yongbo Kang; Yue Cai; Ying Yang
Journal:  Liver Cancer       Date:  2021-12-21       Impact factor: 12.430

Review 2.  Oral-Gut Microbiome Axis in Gastrointestinal Disease and Cancer.

Authors:  Se-Young Park; Byeong-Oh Hwang; Mihwa Lim; Seung-Ho Ok; Sun-Kyoung Lee; Kyung-Soo Chun; Kwang-Kyun Park; Yinling Hu; Won-Yoon Chung; Na-Young Song
Journal:  Cancers (Basel)       Date:  2021-04-28       Impact factor: 6.639

3.  LC/MS-Based Global Metabolomic Identification of Serum Biomarkers Differentiating Hepatocellular Carcinoma from Chronic Hepatitis B and Liver Cirrhosis.

Authors:  Hong Y Pan; Qing Q Wu; Qiao Q Yin; Yi N Dai; Yi C Huang; Wei Zheng; Tian C Hui; Mei J Chen; Ming S Wang; Jia J Zhang; Hai J Huang; Yong X Tong
Journal:  ACS Omega       Date:  2021-01-04

4.  Gut Microbiome Distinguishes Patients With Epilepsy From Healthy Individuals.

Authors:  Guangying Cui; Shanshuo Liu; Zhenguo Liu; Yuan Chen; Tianwen Wu; Jiamin Lou; Haiyu Wang; Yawen Zou; Ying Sun; Benchen Rao; Zhigang Ren; Yajun Lian; Yan Jiang
Journal:  Front Microbiol       Date:  2022-01-07       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.